Belapectin
- Generic Name
- Belapectin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1980787-47-0
- Unique Ingredient Identifier
- K7ODU55HT6
- Background
Belapectin is under investigation in clinical trial NCT02575404 (GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients).
- Associated Conditions
- -
- Associated Therapies
- -
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 357
- Registration Number
- NCT04365868
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Loyola University Health System, Maywood, Illinois, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Galectin Therapeutics Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04332432
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc, Miami, Florida, United States
🇺🇸Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath